Drug discovery and development based on the elucidation of the molecular effects of fingolimod as a modulator of sphingosin-1-phosphate receptors and subsequent clinical studies have led to its approval in 2010 as the first orally active pharmaceutical (brand name Gilenya) for treating multiple sclerosis relapsing forms [63]. Here, S1PR1 is linked to multiple sclerosis.